insights_auto
Why is ZYME up ၂.၈၅%?
Dive Deeperchevron_right
ZYME:NASDAQ
Zymeworks Inc
၂၅.၉၈ US$
arrow_upward
+၂.၈၅%(+၀.၇၂) 1D
အောက် ၉, GMT-၄ ၁၅:၀၈:၂၆ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ZYME...
Open
၂၅.၂၈ US$
High
၂၆.၃၄ US$
Low
၂၅.၂၈ US$
Mkt. cap
၁၈၄.၃၅ ဋေ
Avg. vol.
၈.၆၃ သိန်း
Volume
၂.၇၉ သိန်း
52-wk high
၃၁.၃၄ US$
52-wk low
၁၆.၀၀ US$
EPS
-၂.၀၁ US$
Beta
၁.၁၇
Shares outstanding
၇.၁၀ ကုဋေ
No. of employees
၂၃၁
Open
၂၅.၂၈ US$
High
၂၆.၃၄ US$
Low
၂၅.၂၈ US$
Mkt. cap
၁၈၄.၃၅ ဋေ
Avg. vol.
၈.၆၃ သိန်း
Volume
၂.၇၉ သိန်း
52-wk high
၃၁.၃၄ US$
52-wk low
၁၆.၀၀ US$
EPS
-၂.၀၁ US$
Beta
၁.၁၇
Shares outstanding
၇.၁၀ ကုဋေ
No. of employees
၂၃၁
News stories
From web sources and news partners
Investing.com UK
·
ပြီးခဲ့သည့် ၃ နာရီ
Form 144 Zymeworks Inc. For: 9 October By Investing.com
Stock Titan
·
ပြီးခဲ့သည့် ၄ နာရီ
Officer Adam Schayowitz proposes selling 13,832 shares of Zymeworks (Nasdaq: ZYME).
Simply Wall Street
·
ပြီးခဲ့သည့် ၁ ရက်
Revenue Guidance Might Change The Case For Investing In Zymeworks (ZYME)
GuruFocus
·
ပြီးခဲ့သည့် ၂ ရက်
ZYME Maintains Rating by Truist Securities -- Price Target Raised to $34
Profile
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
About Zymeworks Inc
CEOKenneth Galbraith
Employees၂၃၁
Founded၂၀၀၃
Headquartersဗန်ကူးဗားမြို့, ဗြိတိသျှ ကိုလံဘီယာ ပြည်နယ်, ကနေဒါ
Sector-
Websitezymeworks.com